Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial

被引：11

作者：

Camidge, D. Ross ^{[1
]}

Tiseo, Marcello ^{[2
]}

Ahn, Myung-Ju ^{[3
]}

Reckamp, Karen ^{[4
]}

Hansen, Karin ^{[5
]}

Kim, Sang-We ^{[6
]}

Huber, Rudolf ^{[7
]}

West, Howard ^{[8
]}

Groen, Harry ^{[9
]}

Hochmair, Maximilian ^{[10
]}

Leighl, Natasha ^{[11
]}

Gettinger, Scott ^{[12
]}

Langer, Corey ^{[13
]}

Paz-Ares, Luis ^{[14
]}

Smit, Egbert ^{[15
]}

Kim, Edward ^{[16
]}

Reichmann, William ^{[17
]}

Clackson, Tim ^{[17
]}

Kerstein, David ^{[17
]}

Haluska, Frank ^{[17
]}

Kim, Dong-Wan ^{[18
]}

机构：

[1] Univ Colorado, Ctr Canc, Aurora, CO USA

[2] Univ Hosp Parma, Med Oncol, Parma, Italy

[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Meidicine, Seoul, South Korea

[4] City Hope Comprehens Canc Ctr, Duarte, CA USA

[5] Odense Univ Hosp, Odense, Denmark

[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[7] Univ Hosp Munich, Munich, Germany

[8] Swedish Canc Inst, Med Oncol, Seattle, WA USA

[9] Univ Med Ctr Groningen, Groningen, Netherlands

[10] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria

[11] Princess Margaret Canc Ctr, Med Oncol, Toronto, ON, Canada

[12] Yale Canc Ctr, New Haven, CT USA

[13] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[14] Hosp Univ Doce Octubre, Madrid, Spain

[15] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[16] Carolinas Healthcare Syst, Levine Canc Inst, Solid Tumor Oncol, Charlotte, NC USA

[17] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA

[18] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

ALK; brigatinib; NSCLC; TKI;

D O I：

10.1016/j.jtho.2016.11.1643

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02a-013

引用

页码：S1167 / S1169

页数：3

共 50 条

[1] Brigatinib in crizotinib-refractory ALK1 NSCLC: Updates from the pivotal randomized phase 2 Trial (ALTA)
Hochmair, M. J.
Tiseo, M.
Reckamp, K. L.
West, H. L.
Groen, H. J.
Langer, C. J.
Reichmann, W.
Kerstein, D.
Kim, D-W.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2017, 28
[2] Hypertension With Brigatinib: Experience in ALTA, a Randomized Phase 2 Trial in Crizotinib-Refractory ALK plus NSCLC
Camidge, D. R.
Ahn, M.
Reckamp, K.
West, H.
Huber, R.
Langer, C.
Bazhenova, L.
Leighl, N.
Reichmann, W.
Kerstein, D.
Kim, D.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1893 - S1893
[3] Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial
Ahn, M.
Camidge, D. R.
Tiseo, M.
Reckamp, K.
Hansen, K.
Kim, S.
Huber, R.
West, H.
Groen, H.
Hochmair, M.
Leighl, N.
Gettinger, S.
Langer, C.
Paz-Ares, L.
Smit, E.
Kim, E.
Reichmann, W.
Kerstein, D.
Kim, D.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1755 - S1756
[4] Updated efficacy and safety results from ALTA, a randomized phase 2 trial of brigatinib in crizotinib-refractory ALK plus NSCLC
Hochmair, M.
Ahn, M-J
Camidge, D. R.
Tiseo, M.
Reckamp, K.
Hansen, Holmskov K.
Kim, S-W
Huber, R.
West, H.
Groen, H.
Leighl, N.
Gettinger, S.
Langer, C.
Paz-Ares Rodriguez, L.
Smit, E.
Kim, E.
Reichmann, W.
Kerstein, D.
Kim, D-W
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 271 - 271
[5] Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial
Ahn, Myung-Ju
Camidge, D. Ross
Tiseo, Marcello
Reckamp, Karen L.
Hansen, Karin Holmskov
Kim, Sang-We
Huber, Rudolf M.
West, Howard Jack
Groen, Harry J. M.
Hochmair, Maximilian J.
Leighl, Natasha B.
Gettinger, Scott N.
Langer, Corey J.
Paz-Ares, Luis G.
Smit, Egbert F.
Kim, Edward S.
Reichmann, William
Kerstein, David
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[6] Overall Survival (OS) After Disease Progression (PD) on Brigatinib in Patients With Crizotinib-Refractory ALK plus NSCLC in ALTA
Langer, C.
Huang, H.
Reichmann, W.
Lustgarten, S.
Kerstein, D.
Camidge, D. R.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1893 - S1894
[7] Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALKþ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
Gettinger, Scott N.
Huber, Rudolf M.
Kim, Dong-Wan
Bazhenova, Lyudmila
Hansen, Karin Holmskov
Tiseo, Marcello
Langer, Corey J.
Rodriguez, Luis G. Paz-Ares
West, Howard L.
Reckamp, Karen L.
Weiss, Glen J.
Smit, Egbert F.
Hochmair, Maximilian J.
Kim, Sang-We
Ahn, Myung-Ju
Kim, Edward S.
Groen, Harry J. M.
Pye, Joanna
Liu, Yuyin
Zhang, Pingkuan
Vranceanu, Florin
Camidge, Ross
JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (09):
[8] Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial
Huber, Rudolf M.
Hansen, Karin H.
Paz-Ares Rodriguez, Luis
West, Howard L.
Reckamp, Karen L.
Leighl, Natasha B.
Tiseo, Marcello
Smit, Egbert F.
Kim, Dong-Wan
Gettinger, Scott N.
Hochmair, Maximilian J.
Kim, Sang-We
Langer, Corey J.
Ahn, Myung-Ju
Kim, Edward S.
Kerstein, David
Groen, Harry J. M.
Camidge, D. Ross
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (03) : 404 - 415
[9] Brigatinib (BRG) in Crizotinib (CRZ)-Refractory ALK plus Non-Small Cell Lung Cancer (NSCLC): efficacy and safety results from ALTA, a pivotal randomized phase 2 Trial
Kim, D.
Tiseo, M.
Ahn, M.
Reckamp, K.
Hansen, K. Holmskov
Kim, S.
Huber, R.
West, H.
Groen, H.
Hochmair, M.
Leighl, N.
Gettinger, S.
Langer, C.
Paz-Ares Rodriguez, L.
Smit, E.
Reichmann, W.
Kerstein, D.
Haluska, F.
Camidge, D.
ANNALS OF ONCOLOGY, 2016, 27
[10] Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial
Ou, Sai-Hong Ignatius
Tiseo, Marcella
Camidge, D. Ross
Ahn, Myung-Ju
Huber, Rudolf M.
Hochmair, Maximilian J.
Kim, Sang-We
West, Howard Jack
Reckamp, Karen L.
Molina, Julian R.
Liu, Geoffrey
Delmonte, Angelo
Ramirez, Santiago Viteri
Bearz, Alessandra
Summers, Yvonne J.
Reichmann, William
Kerstein, David
Gettinger, Scott N.
Kim, Dong-Wan
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →